Loading clinical trials...
Loading clinical trials...
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Alkermes, Inc.
NCT06952699 · Narcolepsy Type 2
NCT06251063 · Narcolepsy Type 1, Narcolepsy Type 2, and more
NCT05687916 · Narcolepsy Type 2
NCT04096560 · Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
Alkermes Investigator Site
Little Rock, Arkansas
Alkermes Investigator Site
Los Angeles, California
Alkermes Investigator Site
Redwood City, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions